Marita Ziepert

KMWin – A Convenient Tool for Graphical Presentation of Results from Kaplan-Meier Survival Time Analysis

Markus Scholz, Arnd Gross, Marita Ziepert, 2012, PloS one.

German High-Grade Non-Hodgkin Lymphoma Study Group analysis of patients with T-cell lymphoma treated in studies of the Treatment and prognosis of mature T-cell and NK-cell lymphoma: an

Markus Loeffler, Anthony D. Ho, Norbert Schmitz, 2013 .

Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60).

Markus Loeffler, Anthony Ho, Norbert Schmitz, 2008, The Lancet. Oncology.

Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era.

Dirk Hasenclever, Markus Loeffler, Norbert Schmitz, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes

Stefano Monti, Gad Getz, Ignaty Leshchiner, 2018, Nature Medicine.

Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL.

Michael Hummel, Markus Loeffler, Peter Möller, 2010, Blood.